Poster

SURWEY Study of Solriamfetol: Initiation, Titration, Safety, Efficacy, and Follow-Up Experience for Patients with OSA in Germany

This real-world study examined initiation strategies and subsequent outcomes for solriamfetol (Sunosi®), a wake-promoting agent used to treat excessive daytime sleepiness (EDS) in obstruc...

10/26/2023

Safety and Efficacy of Low-Sodium Oxybate in Participants With Narcolepsy With and Without Psychiatric Comorbidities: Subgroup Analysis of a Phase 3 Clinical Trial

This study assessed safety and efficacy of low-sodium oxybate (LXB) in participants with narcolepsy both with and without comorbid psychiatric disorders in a phase 3 clinical study. Safet...

10/26/2023

Safety and Tolerability of Zuranolone 50 mg in Patients with Major Depressive Disorder: Results from the Phase 3 WATERFALL and CORAL Studies

Zuranolone 50 mg initiated alone (WATERFALL Study) or co-initiated with a standard-of-care antidepressant (CORAL Study) was well-tolerated in adults with major depressive disorder. In WAT...

10/26/2023

Screening for Obsessive Compulsive Disorder among college students using the Obsessive Compulsive Inventory-4

This study aimed to assess the efficacy of the Obsessive Compulsive Inventory questionnaire (OCI-4), a four-item OCD screening tool used to detect OCD, in a cohort of college students. Th...

10/26/2023

Shaping Psychiatric Pharmacy Through Stewardship and Standardized Outcomes

The American Association of Psychiatric Pharmacists (AAPP) has sought to operationalize the concept of psychotropic stewardship through formalizing a consensus-based set of outcomes and m...

10/26/2023

Safety and Efficacy of KarXT in Schizophrenia in the Randomized, Double-Blind, Placebo-Controlled, Phase 3 EMERGENT-3 Trial

In the EMERGENT-3 phase 3 trial, KarXT, a combination of xanomeline (M1/M4 muscarinic receptor agonist) and trospium chloride (muscarinic receptor antagonist), demonstrated significant ef...

10/26/2023

Real-World Antipsychotic and Vesicular Monoamine Transporter Type 2 Inhibitor Treatment Patterns in Patients Newly Diagnosed With Tardive Dyskinesia

Antipsychotic (AP) and vesicular monoamine transporter type 2 inhibitor (VMAT2i) treatment patterns post-tardive dyskinesia (TD) diagnosis are unclear. Deutetrabenazine (DTBZ) is a VMAT2i...

10/26/2023

Real-World Antipsychotic Treatment Modification With and Without Deutetrabenazine in Patients Newly Diagnosed With Tardive Dyskinesia

Tardive dyskinesia (TD) management includes antipsychotic (AP) dose modification/discontinuation, often leaving underlying psychiatric conditions undertreated. Deutetrabenazine (DTBZ) is ...

10/26/2023

Real-World Effectiveness of Deutetrabenazine When Initiated Using a 4-Week Patient Titration Kit: Interim Results of the START Study

START is an ongoing, noninterventional, prospective, single-arm, 2-cohort (tardive dyskinesia [TD] and Huntington disease) study evaluating the effectiveness of deutetrabenazine initiated...

10/26/2023

Real-World Observational Study of Implementation and Evaluation of the Pathway Platform: A Digitally Enabled Care Pathway to Improve Depression Management in Primary Care

The Pathway Platform supports MBC for patients with MDD by integrating a patient-facing app with EHR. This real-world Pathway Platform implementation study in primary care demonstrated si...

10/26/2023